Genetic Counseling: Accessibility and Availability

This activity is part of a series


Banu Arun, MD
Professor, Department of Breast Medical Oncology
Co-Medical Director, Clinical Cancer Genetics Program and Section Chief Breast Genetics, Prevention and Screening
University of Texas MD Anderson Cancer Center
Houston, TX
Banu Arun, MD

Dr. Banu Arun is Professor in Department of Breast Medical Oncology, Co-Medical Director of the Clinical Cancer Genetics Program, and Section Chief Breast Genetics, Prevention and Screening at the University of Texas MD Anderson Cancer Center. Her research focuses on identifying risk biomarkers for breast cancer and prevention and characterizing risk factors in a cohort of high-risk women with hereditary gene mutations (BRCA and others) as well as assessing breast cancer biology in these patients. Dr. Arun has served as the Principal Investigator on several clinical trials evaluating agents such as letrozole, imatinib, gemcitabine, R115777, and PARP inhibitors for metastatic breast cancer and celecoxib, atorvastatin, dasatinib, and Tamoxifen Gel in short-term breast cancer prevention trials. Her research also includes outreach and education, as well as cascade genetic testing of family members.

Given her national and international expertise, she has served on several committees, including The American Society of Clinical Oncology (ASCO) Prevention committee ASCO Prevention Education Committee and currently serves as the Co-Chair for the Southwest Oncology Group (SWOG) Prevention and Epidemiology Committee and member of the NCCN Breast Cancer Risk Reduction Guideline Committee as well as the NCCN Breast Hereditary Genetics Guideline Committee, member of the ASCO Germline Genetic Testing Guideline Panel, and member of the  National Cancer Institute (NCI) Cancer Prevention Steering Committee. She served as grant reviewer for Susan Komen and NCI P01 and reviewed for journals including the Journal of Clinical Oncology, Cancer, British Medical Journal, Cancer Prevention and Epidemiology, amongst others. She has more than 200 peer-reviewed publications and received research grants from the NCI, DoD, Susan Komen Foundation, and CPRIT.

She was featured in Forbes (December 2017) as one of the top 30 Breast Medical Oncologists in the United States. She has received FASCO award recognition in 2020 from the American Society of Clinical Oncology and is the recipient of the ASCO–American Cancer Society Award 2021.


Yevgeniya Ioffe, MD, FACOG, FACS
Associate Professor, Loma Linda University School of Medicine
Chief, Division of Gynecologic Oncology
Loma Linda University Health
Loma Linda, CA
Yevgeniya Ioffe, MD, FACOG, FACS

Dr. Ioffe is a gynecologic oncologist in Southern California. She completed her training in gynecologic oncology at Washington University/Barnes-Jewish Hospital in St. Louis. Her practice focus has included improving care of women afflicted with gynecologic malignancies in the underserved San Bernardino and Riverside counties.

Her academic interest has focused on establishing a fellowship training program in gynecologic oncology in those underserved counties.

Her research interests include: impact of genetic and molecular alterations on treatment and outcome of ovarian cancer and improving genetic testing rates in gynecologic oncology patients.

Statement of Need

Genetic testing has shown promising results to inform and target therapy in cancer; however, uptake is suboptimal due to racial, ethnic, and socioeconomic barriers. Clinicians practicing in the community oncology setting often play the role of genetic counselor to patients with cancer and need support to improve access to necessary, high-quality genetic services for patients of all backgrounds. To achieve this and to facilitate improved patient outcomes, clinicians need to proactively improve awareness and education on genetic counseling.

In the second installment of this CME Outfitters Snack series, expert faculty will discuss strategies for providing high-quality genetic counseling and services for underserved patients with cancer, including leveraging health technology (e.g. telehealth), utilizing a collaborative/interprofessional approach to genetic counseling, and implementing a workable process for patient identification and triage.

Learning Objective

Upon completion of this activity, learners will be able to better employ strategies to provide genetic counseling for patients with cancer.

Financial Support

Supported by an educational grant from Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc.

Target Audience

Physicians, physician associates (PAs), nurse practitioners (NPs), nurses and pharmacists specializing in pathology, oncology or surgical oncology caring for patients with cancer in community settings

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.5 contact hours.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.5 contact hours (0.05 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-23-029-H01-P

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Arun reports the following financial relationships:

Grants: Department of Defense (DOD); Cancer Prevention & Research Institute of Texas (CPRIT); National Cancer Institute (NCI); and Susan G. Komen

Research Support: AstraZeneca (paid to the institution)

Dr. Ioffe reports the following financial relationships:

Advisory Board: Immunogen/GOG Foundation and Seagen

Consultant: Targeted Oncology and OncLive

Research Support: 2021: Pilot study of organoid model of uterine and ovarian carcinosarcomas. Principal investigator, Granted by Research Committee, Department of Gynecology and Obstetrics (Loma Linda University)

2022-2023/4: Grant to promote collaborative and translational research (GCAT). Principal investigator (10% time), Reversing Chemoresistance in Recurrent Ovarian Cancer (Loma Linda University)

Speakers Bureau: OncLive Panel

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report:

  • Joshua Caballero PharmD, BCPP, FCCP (peer reviewer)
  • Thomas Mitchell (planning committee)
  • David Modrak, PhD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Genetic Counseling: Accessibility and Availability
Event Date: 04/17/2023